Neuromuscular pathologies are a recognized complication of SCT, often occurring as a result of infection or haemorrhage, but also in association with GVHD following allogeneic SCT. 1 The published literature on posttransplant peripheral nervous system pathologies includes descriptions of myasthenia gravis, Guillain-Barreś yndrome, polymyositis and peripheral neuropathy. [2] [3] [4] [5] Ocular toxicity, radiculopathy and plexopathy have also rarely been reported. We report three cases of brachial plexopathy occurring after autologous peripheral blood stem cell transplantation (PBSCT).
Case 1
A 64-year-old man was initially treated with adriamycin, carmustine, CY and melphalan for symptomatic multiple myeloma. Following a poor response the patient was switched to oral melphalan, which was continued for 6 months. At first progression, 4 years later, chemotherapy was restarted with VCR, CY, doxorubicin and methylprednisolone . This was followed by an autologous PBSCT with high-dose melphalan (200 mg/m 2 ) conditioning. Fourteen days post-transplant he developed rapidly progressive proximal weakness in both upper limbs. This was associated with pain in both shoulders radiating to both hands. Clinical examination revealed bilateral proximal upper limb weakness with wasting and areflexia. The remainder of the neurological examination was normal.
Magnetic resonance imaging of the cervical spinal cord and brachial plexi was unremarkable but a chest radiograph showed bilateral diaphragmatic paralysis. Nerve conduction studies showed bilateral brachial plexus neuropathy with predominant involvement of the upper trunks. The patient is now 9 years post-transplant and there has been no improvement in the neuropathy.
Case 2
A 62-year-old man underwent autologous PBSCT for treatment of multiple myeloma. At presentation three months previously the patient had received oral CY, thalidomide and dexamethasone as induction chemotherapy. After 2 weeks of thalidomide the patient complained of numbness and paraesthesia in both arms and legs.
Tone and power were normal throughout, lower limb deep tendon reflexes were absent and plantars were downgoing. Magnetic resonance imaging of the whole spine at this point revealed widespread myelomatous involvement of the bony spine but no cord compromise. Thalidomide was continued with no alteration in dosage. The patient subsequently underwent a PBSCT with high-dose melphalan as the conditioning regime.
Within 14 days of stem-cell infusion the patient developed progressive proximal weakness affecting predominantly the upper limbs. There was no neck pain or involvement of bladder or bowel. Examination revealed bilateral wrist-drop with grade 3-4 weakness of the small muscles of the hand, elbow flexors and extensors and shoulder abduction. Upper limb reflexes were absent. The neurological findings in the lower limbs were unchanged.
Neurophysiological testing revealed profound axonal degenerative lesions of upper limb nerves, but not those of the lower limbs, with myopathic concentric needle electrode findings in proximal muscles and a mild sural sensory nerve action potential abnormality. An magnetic resonance imaging scan of the whole spine was repeated and again showed no significant neurological abnormalities. Two years post-transplant the patient's neuropathy continues to improve gradually.
Case 3
A 46-year-old man received high-dose melphalan for treatment of myeloma. Routine blood testing 2 years previously resulted in a diagnosis of asymptomatic myeloma. Six months later the patient developed persistent lower back pain and a skeletal survey revealed lytic lesions in both humeri. Chemotherapy was started with four cycles of idarubicin and dexamethasone followed by high-dose melphalan and PBSCT.
Two weeks post-transplant the patient developed persistent and progressive neuropathic pain in the right hand. This rapidly evolved into paraesthesia and muscle wasting of the right arm. Examination revealed wasting and weakness of the muscles innervated by C5/6, winging of the right scapula, decreased biceps and supinator reflexes on the right side and decreased pin prick sensation in the C5 dermatome. A magnetic resonance imaging scan of the cervical spine showed no significant abnormalities and following a neurological opinion a diagnosis of brachial plexopathy was made. Neurophysiological studies were not performed. Over the subsequent 18 months his myeloma remained stable and his neurological function improved but significant disability persists.
Brachial plexopathy results in the rapid onset of dull pain affecting the shoulder girdle accompanied by weakness of the proximal upper limb, as observed in our cases. Sensory loss is typically less prominent than motor features. Sporadic cases occur in the general population often having a temporal association with infection, vaccination, pregnancy, surgery or drug therapy.
Neuromuscular pathologies after allogeneic BMT are well documented and have variously been attributed to GVHD-induced immune dysregulation, the conditioning chemotherapy and side-effects of immunosuppression. [4] [5] [6] The cases reported here developed brachial plexopathy early after autologous PBSCT with two of the cases having no neurological symptoms before PBSCT. The remaining case had a pre-existing thalidomide-induced sensory peripheral neuropathy, but developed a second distinct neurological lesion after PBSCT. Neurophysiological testing on this patient revealed a sensory nerve action potential that was only mildly reduced. This is in contrast to the greater than 50% reduction characteristically seen with thalidomide-related neuropathy, which is typically sensory rather than motor. 7, 8 Toxicity from induction chemotherapy seems an unlikely cause for the brachial plexopathies occurring in these cases as the patients had received three different chemotherapy regimens before their PBSCT. All three received high-dose melphalan as the conditioning regimen, which is not thought to be associated with neuromuscular toxicity. Paraneoplastic neuropathy also seems unlikely as the onset followed PBSCT in each case.
In previously reported cases (unrelated to PBSCT) brachial plexus biopsy specimens have revealed inflammatory infiltrates and cultured PBLs have been demonstrated to increase their mitogenic activity in response to brachial plexus nerves. 9, 10 These observations support an autoimmune theory of pathogenesis. There is a delay in immune reconstitution following autologous PBSCT and a loss of self-tolerance resulting in autoimmune phenomena is documented in both the allogeneic and autologous setting. 11, 12 We suggest that the neuromuscular sequelae of PBSCT described here result from an autoimmune process targeting peripheral nervous system antigens as opposed to a toxic effect of previously administered drugs. Identification of demyelinating as opposed to axonal features on neurophysiological testing would further strengthen this hypothesis. This distinction was not possible in our patients and is likely to prove difficult in patients with pre-existing severe axonal neuropathy from neurotoxic chemotherapy.
The cases presented here received PBSCT over a 7-year period, with an average of 12.3 patients per year receiving PBSCT with this conditioning regimen for multiple myeloma in our institution over this period. Brachial plexopathy is therefore an uncommon but potentially debilitating complication of autologous PBSCT with none of our cases experiencing complete resolution of their neurological symptoms after prolonged periods of follow-up.
